Non-Invasive Neurostimulation Devices Market, 2020-2030

Overview

Over the past few decades, the prevalence of neurological disorders has been increasing at an alarming rate, particularly among the geriatric population across the world. In fact, a Global Burden of Disease study suggested that neurological conditions, which are often associated with serious physical, cognitive and psychosocial impairment, are currently considered among the major threats to public health. Presently, nearly one million Americans are reported to be living with Parkinson’s disease, and approximately 60,000 new cases are reported every year. Chronic pain is another debilitating condition, contributing to the global economic and healthcare burden. According to the Centers for Disease Control and Prevention, around 50 million individuals in the US suffer from some form of pain. This is estimated to account for a financial burden of USD 560 billion per year, including medical expenses and lost productivity. Although, there are several pharmacological options available for symptomatic relief, they are significantly limited in terms of providing long term solutions. For instance, long-term use of opioid drugs is associated with a high risk of addiction, eventually causing many patients to abuse such interventions. There are also some surgical procedures that are recommended in severe cases, but cannot provide permanent relief, often leading to further complications.

Over the years, advances in neurotechnology and neuroimaging, along with the growing understanding of neurocircuitry, have brought about noticeable disruption in this field. Leveraging the aforementioned intellectual capital, a variety of neurostimulation technologies focused on providing therapeutic relief have been developed. The first neurostimulation therapy was introduced in the 1960s. Since then, the benefits of neurostimulation technologies, such as their reversible and minimally invasive nature, targeted and adjustable therapeutic action, integrated safety mechanisms, and almost negligible dependence on opioids/oral medications, have been widely recognized. In fact, many such technologies are presently perceived to be viable alternatives to conventional treatment methods. Although they were initially considered a last resort for treatment, studies have shown neurostimulation devices to be capable of successfully providing therapeutic relief to medication-resistant patients. As a result, the adoption of these non-invasive solutions is on the rise in the US, EU and other parts of the world. Numerous partnerships have been inked amongst stakeholders in this domain, indicative to future growth of the market. Interestingly, start-ups/university spin-offs have been the flagbearers in this upcoming field of therapeutics and are also expected to sustain the research momentum, over the coming years.

Scope Of the Report

The ‘Non-Invasive Neurostimulation Devices Market, 2020-2030’ report features an extensive study of the current market landscape and the future potential of non-invasive neurostimulation devices in treating different chronic conditions. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain.

In addition to other elements, the study includes:

• A detailed assessment of the overall landscape of the non-invasive neurostimulation devices market, highlighting the contribution of industry players and providing information on various types of non-invasive neurostimulation devices (transcutaneous electrical nerve stimulation (TENS), transcranial magnetic stimulation (TMS), electromagnetic stimulation (EMS), non-invasive vagus nerve stimulation (nVNS) and others), target therapeutic areas (pain management, inflammatory disorders, neurological disorders, psychological disorder, movement disorders and others), regulatory/development status (USFDA, CE Mark, Health Canada, TGA Australia, CFDA, MHLW and others), and the key device specifications, including number of stimulation modes, number of electrodes, size, weight, battery type, regulatory stance, professional assistance requirement and regulatory/reimbursement status.
• An insightful competitiveness analysis of various non-invasive neurostimulation devices, including TENS, TMS, EMS, nVNS and others, taking into consideration the supplier power and product specifications.
• Elaborate profiles of the key players developing non-invasive neurostimulation devices. Each company profile features an overview of the company, its financial information (if available), a detailed description of the device(s), recent developments and an informed future outlook.
• An elaborate discussion on the regulatory landscape for market authorization of medical devices, as well as the guidelines related to their reimbursement across different countries.
• An in-depth analysis of the patents that have been filed/granted for non-invasive neurostimulation devices since 2016, highlighting key trends associated with these patents, across type of patents, publication year, issuing authority/patent offices involved, CPC symbols, emerging focus areas, leading players, patent characteristics and geography. It also includes a detailed patent benchmarking and valuation analysis.
• An analysis of the partnerships that have been inked by the stakeholders in this domain since 2016, covering distribution agreements, research agreements, clinical trial agreements, commercialization agreements, merger and acquisition, licensing agreements, product development and commercialization and research and development agreements.
• A discussion on the upcoming opportunities/trends in the field of non-invasive neurostimulation devices that are likely to impact the evolution of this market over the coming years.

One of the key objectives of the report was to estimate the existing market size and potential growth opportunities for non-invasive neurostimulation devices. Based on parameters, such as target consumer segments, likely adoption rates and expected pricing, we have provided an informed estimate on the likely evolution of the market over the period 2020-2030. The report also features the likely distribution of the current and forecasted opportunity within the non-invasive neurostimulation devices market across [A] type of stimulation technology (TENS/TMS/nVNS/other types), [B] target indication (chronic pain/epilepsy/major depressive disorder/migraine), and [C] key geographical regions (US/Canada/UK/Germany/France/Spain/Italy/Australia/China/Japan). In order to account for the uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios namely the conservative, base and optimistic scenarios, which represent three different tracks of the industry’s evolution.

The opinions and insights presented in the report were influenced by discussions held with senior stakeholders in the industry.

The report features detailed transcripts of interviews held with the following industry stakeholders:

• Chip Fisher (Chairman, Fisher Wallace Laboratories)
• Renee C. Ryan (Chief Executive Officer, Cala Health)
• Sree N Koneru (Vice President, Product Development, BioElectronics)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.